Premium
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program
Author(s) -
Keshelava Nino,
Houghton Peter J.,
Morton Christopher L.,
Lock Richard B.,
Carol Hernan,
Keir Stephen T.,
Maris John M.,
Reynolds C. Patrick,
Gorlick Richard,
Kolb E. Anders,
Wu Jianrong,
Smith Malcolm A.
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21988
Subject(s) - vorinostat , medicine , in vivo , histone deacetylase inhibitor , pharmacology , preclinical testing , in vitro , cancer research , histone deacetylase , oncology , histone , biology , medical physics , biochemistry , microbiology and biotechnology , gene
Vorinostat, a histone deacetylase inhibitor, was evaluated against the in vitro and in vivo childhood solid tumor and leukemia models in the Pediatric Preclinical Testing Program (PPTP). In vitro testing was performed by the DIMSCAN cytotoxicity assay. In vivo, vorinostat was administered intraperitoneally to mice bearing xenografts. Vorinostat demonstrated 2‐log cell growth inhibitory activity in vitro, but generally at concentrations not sustainable in the clinic. No objective responses were observed for any of the solid tumor or acute lymphoblastic leukemia xenografts. Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers. Pediatr Blood Cancer 2009;53:505–508. © 2009 Wiley‐Liss, Inc.